Summary of Recommendations

Document Overview

Design and created by Guideline Central in participation with the Cancer Care Ontario.

Bone Health and Bone-Targeted Therapies for Prostate Cancer

Cancer Care Ontario

Publication Date: Jun 3, 2025

Page Last Updated: May 5, 2026

Document Overview

Document Title: Bone Health and Bone-Targeted Therapies for Prostate Cancer

Authoring Society: Cancer Care Ontario

Document Publication Date: Jun 3, 2025

Page Last Reviewed/Updated: May 5, 2026

Document Type: Consensus Statement

Country of Publication: Canada

Full Text Freely Available: Yes

Full Text Guideline: www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/31716

Source Citation: Alibhai S, Zukotynski K, Walker-Dilks C, Emmenegger U, Finelli A, Morgan S, Hotte S, Winquist E. Bone health and bone targeted therapies for prostate cancer. Alibhai S, Sivajohanathan D, reviewers. Toronto (ON): Cancer Care Ontario; 2016 September 23; Endorsed 2025 June 3. Program in Evidence-based Care Guideline No.: 3-14 Version 3 ENDORSED.

Document Scope, Criteria, and Use Cases

Document Objectives: To evaluate the effectiveness of therapies targeting bone across all stages of prostate cancer.

Scope: Management

Diseases/Conditions (MeSH)

D011467 - Prostate

D011467 - Prostate

Keywords: Bone-Targeted Therapies, prostate cancer

Target Patient Population: Men with prostate cancer

Target Provider Population: Oncologists, urologists, radiologists and other clinicians and HCPs who treat genitourinary cancer

Inclusion Criteria: Male, Adult, Older Adult

Health Care Settings: Ambulatory, Outpatient, Radiology Services

Intended Users: Nurse, Nurse Practitioner, Physician, Physician Assistant

Recommendation Development Processes & Methodology

PICO Questions

Can therapeutic interventions reduce osteoporosis-related outcomes in men with prostate cancer receiving androgen deprivation therapy (ADT)?
Can therapeutic interventions prevent bone metastases in men with prostate cancer?
Can bone-targeted therapies reduce the incidence of SREs, reduce pain, or improve quality of life in men with prostate cancer metastatic to bone?
Can bone-targeted therapies improve overall survival in men with established prostate cancer and bone metastases?